JUMP Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients (JUMP)

Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients

Therapeutic advances in oncology have transformed the prognosis of cancer patients, placing a significant number of them either in a context of recovery or in prolonged remission close to a chronic disease. Thus, the reconquest of a life after cancer becomes possible but raises many challenges for the patient, his entourage, the medical profession and our society. One of the major challenges is the detection and management of treatment side effects for all patients. In addition to the standard organic assessment (glycaemia, creatinine, liver test, blood count), we are mainly interested in muscle deconditioning and cognitive impairment, which are particularly disturbed in these populations. After the evaluation day, patients are referred to the most appropriate structures (Adapted physical activity, sports for health, and rehabilitation at Henry Gabriel Hospital).

JUMP research is part of axis 2 of the 2021-2030 cancer plan: "Limiting sequelae and improving quality of life", through sheets 1 (research) / 6 (access and quality) / 7 (prevention). This leads to the concrete implementation on the territory of adapted care channels in the city: medical structure, physiotherapy, Adapted Physical Activity (APA) structures, associative structures; which makes it possible to develop and strengthen the city-hospital link. Finally, it allows the patient to take ownership and get involved in the project, allowing in the future to make them truly active in they care and to advise and motivate their peers.

This study is non-interventional, it uses research on data that is already collected as part of conventional care, during the JUMP evaluation day.

This study allows the investigators to constitute a cohort of patients to study different parameters related to the disease or to the treatments received.

Our main objective in this study is to describe the muscular and neurocognitive impairment of post-cancer patients evaluated as part of the JUMP program.

Study Overview

• Status: Recruiting
• Conditions: Cancer; Sarcopenia
• Intervention / Treatment: Drug: Study of the adverse effects of long-term oncological treatments; Behavioral: Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

• Study Contact: Name: Cyrille CONFAVREUX, MD; Phone Number: +334 78 86 12 31; Email: Cyrille.confavreux@chu-lyon.fr

Study Locations

• France
  • Pierre-Bénite, France, 69310
    • Recruiting
    • Service de Rhumatologie, Hospices Civils de Lyon, Groupement Hospitalier Lyon Sud
    • Contact: Cyrille CONFAVREUX, PR; Phone Number: +33 4 78 86 12 31; Email: Cyrille.confavreux@chu-lyon.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 74 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

patients who have been treated for cancer and who have completed the post-cancer assessment day

Description

Inclusion Criteria:

• Age : 18 to 74 years
• localization of the primitive: breast, lung, melanoma, testicle, bladder, kidney, ovary, colon and pancreas, hemopathy
• patient who benefited from the post-cancer assessment day-

Exclusion Criteria:

• Under 18years
• Over 74 years
• Patient who did not received any chemical treatment
• Patient who do not wish to participate

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

JUMP Cohort; This study concerns adults with cancer treated with chemotherapy, radiotherapy, hormonal therapy or immunotherapy, in remission or cured. Patients took part in the dedicated post-cancer assessment day.

Drug: Study of the adverse effects of long-term oncological treatments; Cognitive and muscular evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts; Behavioral: Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients; Cognitive and anxiety-depressive evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of patients with physical and neurocognitive impairment	Number of patients whose medical assessments show altered physical, cognitive or anxiety/dpression activity compared to the measurement in the general population	at least 1 year later after chemical treatments

Collaborators and Investigators

• Sponsor: Hospices Civils de Lyon

Study record dates

Study Major Dates

• Study Start (Actual): February 10, 2025
• Primary Completion (Estimated): February 10, 2029
• Study Completion (Estimated): February 10, 2029

Study Registration Dates

• First Submitted: March 24, 2023
• First Submitted That Met QC Criteria: March 24, 2023
• First Posted (Actual): April 5, 2023

Study Record Updates

• Last Update Posted (Actual): November 21, 2025
• Last Update Submitted That Met QC Criteria: November 18, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Keywords: Sarcopenia; Chemobrain; Post cancer; Medical evaluation
• Additional Relevant MeSH Terms: Neurologic Manifestations; Nervous System Diseases; Neuromuscular Manifestations; Mental Disorders; Pathological Conditions, Anatomical; Neurocognitive Disorders; Cognition Disorders; Chemically-Induced Disorders; Drug-Related Side Effects and Adverse Reactions; Muscular Atrophy; Atrophy; Cognitive Dysfunction; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Chemotherapy-Related Cognitive Impairment; Neoplasms; Sarcopenia
• Other Study ID Numbers: 813; 69HCL23_0177 (Other Identifier: HCL)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No